Agilon beats, raises outlook on risk-adjustment upside

 

Agilon Health beats Q1 2026 estimates and raises 2026 revenue and EBITDA outlook on risk-adjustment upside

• Q1 2026 revenue $1.42B (-7% YoY), net income $49M and adjusted EBITDA $54M reported for the quarter.
• Non-GAAP EPS $1.80 increased 146% YoY in Q1 2026 financial results.
• Q1 beat internal guidance on revenue, medical margin, and EBITDA, driven by risk-adjustment uplift.
• 2026 revenue guidance raised to $5.68-$5.81B with higher medical margin and EBITDA outlook, signaling confidence in improved data and contracting.
• Membership declined due to market and payer exits as company prioritizes profitability over growth.
• Medical cost trend remains elevated and Part D exposure/reserving still introduces earnings uncertainty.
• AI-enabled clinical pathways, especially heart failure, are showing tangible utilization and quality improvements.
• ACO REACH delivered strong Q1 EBITDA aided by one-time CMS fraud-related benchmark adjustment.
• Enhanced data pipeline supports higher estimated risk scores, improving visibility and predictability of results.
• Payer contracting for 2026 added meaningful rate benefit, while 2027 talks focused on margin protection.
• Main concern: Sustainability of margin improvement amid elevated cost trends and ongoing Part D and policy risk.
• Strong quarter, driven by higher risk-adjustment revenue, favorable medical cost development, and disciplined contracting.

https://finviz.com/quote?t=AGL&p=d

Russia downs 50 drones headed for Moscow

 Russian air defenses shot down 50 Ukrainian drones flying toward Moscow on Thursday, according to the city's Mayor Sergey Sobyanin.

The last attack occurred during the afternoon hours, Sobyanin wrote on Telegram. Emergency services were activated to deal with the situation due to the danger posed by debris, he added.

Previously, Russia threatened to directly target Kiev and Ukrainian decision-making centers if the war-torn country attempted to disrupt Victory Day Parade celebrations on May 9 in Moscow. Furthermore, Russia's Foreign Ministry urged foreign nationals and diplomats to leave the Ukrainian capital ahead of possible retaliation against the city.

https://breakingthenews.net/Article/Russia-downs-50-drones-headed-for-Moscow/66244820

eHealth posts Q1 2026 loss of $0.58 per share, adjusted loss $0.30, on revenue of $88 million

 

eHealth posts Q1 2026 loss of $0.58 per share, adjusted loss $0.30, on revenue of $88 million

• Board member Cesar Soriano will resign from eHealth's board effective June 2026

https://finviz.com/quote?t=EHTH&p=d

Mineralys FDA acceptance of lorundrostat NDA for uncontrolled hypertension, Dec 22 PDUFA

 

Mineralys gets FDA acceptance of lorundrostat NDA for uncontrolled hypertension with Dec 22 2026 PDUFA date, prepares U.S. launch, seeks global partner

• Company preparing U.S. launch focused on fourth-line resistant patients, expanding to third-line over time.
• Management still seeking a global partner but building stand-alone commercial capability to preserve flexibility.
• Differentiation versus baxdrostat centers on Advance-HTN data, proteinuria effects, and diverse trial populations.
• Payers reportedly receptive to covering fourth-line resistant patients and maintaining parity access between ASIs.
• Physicians value lorundrostat's absolute systolic reduction, roughly nineteen millimeters, and inclusive Black representation.
• Safety profile remains consistent in open-label extension, and long-term durability and tolerability data publication is planned.
• Reports fiscal Q1 2026 non-GAAP EPS $-0.47 (+41% YoY) on revenue $0, beating EPS and revenue estimates.
• Q1 2026 net loss was $39.3 million, as R&D decreased while G&A ramped.
• Cash and investments of $646.1 million expected to fund operations and programs into 2028.
• Main risk is competitive launch, pricing, and access dynamics versus first-to-market AstraZeneca baxdrostat.
• Main concern: Executing differentiation and securing attractive access versus AstraZeneca’s baxdrostat while partnership timing remains uncertain.
• Mixed quarter, driven by NDA acceptance, launch readiness spending, and ongoing but unresolved partnering discussions.

https://finviz.com/quote?t=MLYS&p=d

Acadia misses estimates but reaffirms 2026 outlook and pivotal ADP catalyst

 

Acadia Q1 2026 revenue $268M (+11% YoY), EPS $0.02 (-82% YoY), misses estimates but reaffirms 2026 outlook and pivotal ADP catalyst

• Q1 revenue $268M, +11% YoY adjusted; both DAYBUE and NUPLAZID grew solidly.
• DAYBUE sales $101M, +20% YoY, boosted by strong initial DAYBUE STIX uptake.
• NUPLAZID sales $167M, +6% YoY; 8% demand, 11% referral growth despite refill delays.
• 2026 revenue guidance $1.22–$1.28B and brand-level sales and expense guidance reaffirmed; back-half weighted.
• Remlifanserin Phase II in Alzheimer's psychosis on track for August–October 2026 readout.
• Trofinetide Japan Phase III enrollment ahead of plan; top-line data expected September–November 2026.
• Cash balance $851M, positive operating cash flow, supporting internal pipeline and business development optionality.
• SG&A up to $171M from $126M, reflecting sales force expansion and marketing spend.
• European trofinetide reexamination ongoing; decision expected by late June, potential EU Rett opportunity.
• R&D head retiring year-end; remains through key remlifanserin milestones, but succession introduces transition risk.
• Main concern: High-impact remlifanserin Alzheimer's psychosis data and European trofinetide decision could materially alter outlook.
• Strong quarter, driven by robust DAYBUE growth, stable NUPLAZID demand, and reaffirmed 2026 guidance.

https://finviz.com/quote?t=ACAD&p=d

Castle ups guidance on strong test volumes

 

Castle Biosciences beats Q1 2026 estimates with non-GAAP EPS -$0.49, revenue $84.2M, raises 2026 guidance to $345–355M on robust test volumes

• Non-GAAP EPS of -0.49 improved 46% year over year in fiscal Q1 2026.
• Q1 2026 revenue of $84.2M declined 3% year over year.
• Revenue $83.7m; core test volumes +36% YoY, driven by melanoma and TissueCypher.
• Full-year 2026 revenue guidance raised to $345–355m from $340–350m, excluding SCC/IDgenetix.
• TissueCypher test reports 11,745 (+58% YoY); slight sequential dip attributed to GI seasonality.
• DecisionDx-Melanoma reports 10,021 (+16% YoY); management still guides mid- to high-single-digit 2026 growth.
• AdvanceAD-Tx received ~650 orders in limited rollout; reimbursement clarity expected by Q3 2026.
• Gross margin 72.8% vs 49.2% prior-year; adjusted gross margin down to 75.6%.
• Net loss improved to $14.5m; operating cash outflow $22.1m; cash balance $261.7m.
• Key risks: reimbursement outcomes for AdvanceAD-Tx and DecisionDx-SCC, NCCN guideline headwinds in melanoma.
• Management tone confident; highlighting record March/April volumes and intent to leverage sub-100-rep salesforce.
• Analysts focused on TissueCypher ramp, AD-Tx monetization path, margins, M&A strategy, and Medicare reconsiderations.
• Main concern: Uncertain reimbursement and coverage decisions for key existing and new tests.
• Strong quarter, driven by robust test volume growth and a modest guidance raise.

https://finviz.com/quote?t=CSTL&p=d

Adma pulls long term outlook

 

Adma Biologics misses Q1 EPS and revenue estimates with non-GAAP EPS $0.19 (+40% YoY), revenue $114.5M, maintains 2026 guidance, withdraws long-term outlook

• Q1 2026 revenue was $114.5 million, essentially flat year-over-year, while adjusted net income grew 22% year-over-year.
• Q1 net income totaled $45.3 million, or $0.19 per share, according to the company.
• Company maintained FY 2026 revenue guidance at $530–$560 million but withdrew its long-term outlook amid increasing competition in the IG market.
• Company said an internal audit found no evidence of alleged channel stuffing or undisclosed related-party transactions.

https://finviz.com/quote?t=ADMA&p=d